Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.68)
# 156
Out of 5,182 analysts
140
Total ratings
53.97%
Success rate
43.91%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Upgrades: Buy | $3 → $9 | $3.13 | +187.54% | 3 | Apr 10, 2026 | |
| TBPH Theravance Biopharma | Maintains: Neutral | $14 → $17 | $16.79 | +1.28% | 3 | Apr 7, 2026 | |
| HROW Harrow | Reiterates: Buy | $74 → $65 | $40.90 | +58.92% | 5 | Apr 7, 2026 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $3 → $4 | $1.53 | +161.44% | 3 | Mar 25, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $26 | $8.91 | +191.81% | 1 | Mar 24, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $22 | $8.63 | +154.92% | 3 | Mar 18, 2026 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $105 → $150 | $86.46 | +73.49% | 4 | Feb 23, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $90 → $108 | $63.35 | +70.48% | 6 | Jan 21, 2026 | |
| IRD Opus Genetics | Initiates: Buy | $9 | $5.14 | +75.10% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $39.57 | +6.14% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 → $40 | $26.61 | +50.32% | 2 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.49 | +167.26% | 1 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 → $16 | $8.04 | +99.00% | 20 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $560 | $513.72 | +9.01% | 13 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $33.85 | +62.48% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.00 | +566.67% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $2.82 | +538.30% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.40 | +257.14% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $13.87 | +44.20% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $18.30 | +91.26% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $74.81 | -49.20% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $30.00 | +220.00% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.28 | +17.19% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $10.58 | +1,223.25% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $4.19 | +2,047.97% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.84 | +4,066.67% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.88 | +165.96% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.33 | +3,762.66% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.51 | +363.58% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $0.75 | +596,400.53% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.68 | +160,614.29% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.57 | +252,044.98% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.27 | +76.21% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $87.94 | -55.65% | 2 | Mar 18, 2020 |
MacroGenics
Apr 10, 2026
Upgrades: Buy
Price Target: $3 → $9
Current: $3.13
Upside: +187.54%
Theravance Biopharma
Apr 7, 2026
Maintains: Neutral
Price Target: $14 → $17
Current: $16.79
Upside: +1.28%
Harrow
Apr 7, 2026
Reiterates: Buy
Price Target: $74 → $65
Current: $40.90
Upside: +58.92%
Lineage Cell Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $3 → $4
Current: $1.53
Upside: +161.44%
Climb Bio
Mar 24, 2026
Initiates: Buy
Price Target: $26
Current: $8.91
Upside: +191.81%
Arcturus Therapeutics Holdings
Mar 18, 2026
Initiates: Buy
Price Target: $22
Current: $8.63
Upside: +154.92%
Nektar Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $105 → $150
Current: $86.46
Upside: +73.49%
Cytokinetics
Jan 21, 2026
Maintains: Buy
Price Target: $90 → $108
Current: $63.35
Upside: +70.48%
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $5.14
Upside: +75.10%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $39.57
Upside: +6.14%
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $26.61
Upside: +50.32%
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $4.49
Upside: +167.26%
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $8.04
Upside: +99.00%
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $513.72
Upside: +9.01%
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $33.85
Upside: +62.48%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $3.00
Upside: +566.67%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $2.82
Upside: +538.30%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.40
Upside: +257.14%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $13.87
Upside: +44.20%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $18.30
Upside: +91.26%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $74.81
Upside: -49.20%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $30.00
Upside: +220.00%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.28
Upside: +17.19%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $10.58
Upside: +1,223.25%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $4.19
Upside: +2,047.97%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.84
Upside: +4,066.67%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.88
Upside: +165.96%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.33
Upside: +3,762.66%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.51
Upside: +363.58%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $0.75
Upside: +596,400.53%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.68
Upside: +160,614.29%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.57
Upside: +252,044.98%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.27
Upside: +76.21%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $87.94
Upside: -55.65%